We came across a bullish thesis on Syndax Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SNDX. Syndax Pharmaceuticals, Inc.'s share was trading at $20.67 as of January 15th.
[caption id="attachment_571480" align="aligncenter" width="750"]Syndax Pharmaceuticals has transitioned into a commercial-stage biotech anchored by two first-in-class approved therapies, Revuforj (revumenib) and Niktimvo (axatilimab), each addressing areas of high unmet medical...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.